A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

More documents

Recommendations

Info

cGVHD Manifestions – NIHFilipovich BBMT 2005;11:945 and asbmt.orgFor each organ system manifestations are:• Diagnostic – sufficient to make a diagnosis• Distinctive – needs extra test, clinical, biopsy etc• Other – Rare, controversial, non-specific• Common (shared by both acute and chronic)Diagnostic process:• Presence of at least 1 Diagnostic OR 1 Distinctive + biopsy etc.• Distinguish from acute GVHD• Exclude other possible diagnoses
cGVHD Assessment by NIHFilipovich BBMT 2005;11:945-55 and asbmt.org• Diagnosis (Diagnostic/Distinctive)• Organ Scoring• Global Scoring• Performance Score (Function)– Walk time– Grip Strength– Karnofsky
Page 1 and 2: A Randomized Trial of Thymoglobulin
Page 3 and 4: Appendix AIllustrations of cGVHD -
Page 5: Quality of LifeFraser CJ et al. Imp
Page 12 and 13: A Randomized Trial of Thymoglobulin
Page 14 and 15: FundingTOTAL GRANT:CIHR:$1,245,055
Page 16 and 17: FinkeLancet Oncol 2009;10: 855-64Ba
Page 18 and 19: Time to Onset of Prednisone RxMielk
Page 20 and 21: Secondary End-Points• Time to eng
Page 22 and 23: Treatment Plan - ThymoglobulinThe e
Page 24 and 25: Flu-Bu-ATG (Slavin) vs F-TBI (Seatt
Page 26 and 27: Benefits and Harms• BENEFITS• L
Page 28 and 29: PTLD in Unrelated/Mismatch +ATGStud
Page 30 and 31: Performance of QPCR test for EBVAss
Page 34 and 35: cGVHD Case Report Form (CRF)
Page 36 and 37: cGVHD Case Report Form (CRF)
Page 38 and 39: Body Surface Area (Rule of 9)
Page 40 and 41: Will CBMTG 0801 succeed?In part for
Page 42 and 43: Flowers ME, Storer BE, Lee SJ, et a
Page 44: Thank you

A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?